EcoDrugPlus

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSCHYG00000009628
Gene Symbol: AGTR2
1 Cross references
195 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSCHYG00000012752
Gene Symbol: APH1A
1 Cross references
138 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSCHYG00000006935
Gene Symbol: APH1B
1 Cross references
193 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSCHYG00000019773
Gene Symbol: ALOX12
1 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSCHYG00000013412
Gene Symbol: ALOX5
1 Cross references
222 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSCHYG00000015250
Gene Symbol: ALOX5AP
1 Cross references
201 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSCHYG00000004018
Gene Symbol: AVPR1A
1 Cross references
268 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSCHYG00000005177
Gene Symbol: AVPR1B
1 Cross references
135 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCHYG00000025838
Gene Symbol: AVPR2
1 Cross references
251 Possible Orthologues:

Aryl Hydrocarbon Receptor

Ensembl ID : ENSCHYG00000008314
Gene Symbol: AHR
1 Cross references
155 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSCHYG00000020501
Gene Symbol: AURKA
1 Cross references
233 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSCHYG00000016171
Gene Symbol: AURKB
1 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).